

B'SYS GmbH

# CHO K<sub>v</sub>LQT1/minK Cell Line

Application Note

© B'SYS GmbH

---

## TABLE OF CONTENTS

<b>1</b>	<b>BACKGROUND.....</b>	<b>3</b>
1.1	THE CARDIAC IKs CURRENT IS ENCODED BY KvLQT1/MINK .....	3
1.2	COEXPRESSION OF KvLQT1 AND MINK .....	3
1.3	B'SYS'S CHO KvLQT1/MINK CELLS.....	3
<b>2</b>	<b>PRODUCT SHIPMENT .....</b>	<b>4</b>
2.1	PRODUCT FORMAT.....	4
2.2	MYCOPLASMA CERTIFICATE.....	4
<b>3</b>	<b>VALIDATION OF CHO KvLQT1/MINK CELLS .....</b>	<b>5</b>
3.1	ELECTROPHYSIOLOGY.....	5
3.2	PHARMACOLOGICAL VALIDATION .....	6
3.3	PATCH-CLAMP SUCCESS RATES.....	7
<b>4</b>	<b>KvLQT1/MINK SEQUENCE .....</b>	<b>8</b>
4.1	HUMAN KvLQT1 ACCESSION NUMBER AF000571.....	8
4.2	HUMAN MINK SUBUNIT ACCESSION NUMBER AF135188 .....	8
<b>5</b>	<b>CONTACT INFORMATION.....</b>	<b>9</b>
5.1	CONTACT ADDRESS FOR TECHNICAL SUPPORT & ORDERING INFORMATION .....	9

---

## 1 BACKGROUND

### 1.1 The cardiac I<sub>Ks</sub> current is encoded by KvLQT1/minK

Like the native cardiac I<sub>Kr</sub> current (encoded by HERG channel), also the I<sub>Ks</sub> current to a large extent is responsible for the termination of the cardiac action potential. Inherited mutations in KvLQT1 potassium channel (KCNQ1) and the associated minK subunit (KCNE1) can cause the Long QT Syndrome 1 and Long QT Syndrome 5, respectively.

### 1.2 Coexpression of KvLQT1 and minK

The paired expression of the KvLQT1  $\alpha$  subunit along with the minK  $\beta$  subunit in a suitable expression system results in potassium currents resembling the native I<sub>Ks</sub> current. The most apparent effect of the minK  $\beta$  subunit on KvLQT1 currents is an about tenfold decrease of the activation kinetics as compared to currents from KvLQT1 channels alone.

### 1.3 B'SYS's CHO KvLQT1/minK Cells

B'SYS has designed a new CHO KvLQT1/minK cell line with constitutive co-expression of human KvLQT1/minK channels. The human KvLQT1/minK cDNA was cloned and transfected into CHO cells and then the functional properties of the KvLQT1/minK channels validated by means of the patch-clamp technique. Cells were validated for manual and automated patch-clamping (Sophion Q-Patch™). Results are outlined in section 3.

## 2 PRODUCT SHIPMENT

### 2.1 Product Format

CHO cells stably transfected with recombinant human KvLQT1/minK channel:

- 1 x 0.5 mL aliquots of frozen cells at 2.3 E+06 cells/mL
- Cells are frozen in complete medium with 10% DMSO

### 2.2 Mycoplasma Certificate

B'SYS periodically tests cells for presence of mycoplasma by means of highly sensitive PCR based assays. All delivered cells are free of mycoplasma.

### 3 VALIDATION OF CHO KvLQT1/MINK CELLS

#### 3.1 Electrophysiology

KvLQT1/minK currents were measured by means of the patch-clamp technique in the whole-cell configuration. The bath solution contained (in mM) NaCl 145, KCl 4, CaCl<sub>2</sub> 2, MgCl<sub>2</sub> 1, D-glucose 10, HEPES 10, pH (NaOH) 7.40 ~305 mOsm. The pipette solution consisted of (in mM) KF 120, KCl 20, HEPES 10, EGTA 10, EDTA 10, pH (KOH) 7.20 ~290 mOsm. After formation of a GΩ seal between the patch electrodes and individual KvLQT1/minK stably transfected CHO cells, the cell membrane across the pipette tip was ruptured to assure electrical access to the cell interior. All solutions applied to cells were continuously perfused and maintained at room temperature. As soon as a stable seal could be established potassium currents were measured upon depolarization of the cell membrane from a holding potential of -80 mV to +120 mV in 20 mV increments of 4 seconds duration (Fig. 1). KvLQT1/minK deactivating tail currents were elicited upon partial repolarization to -40 mV for 1 s. The voltage pulses were run at intervals of 10 s.




Fig.1: Activation of KvLQT1/minK. Outward currents were observed upon depolarization of the cell membrane from holding potential (-80 mV) up to +120 mV in 20 mV increments. Top left: manual patch-clamping, top right voltage protocol, middle left: automated patch-clamping, Q-Patch, middle right: IV curve. Bottom left: repetitive stimulation of KvLQT1 / minK, bottom right: IT plot shows only minimal decrease of the current amplitude.

### 3.2 Pharmacological Validation

In order to evaluate the pharmacological properties of the KvLQT1/minK channel. The response of KvLQT1/minK to a known blocker XE-991 was tested. Four concentrations were tested 0.01, 0.1, 1, 10  $\mu\text{M}$ . An  $\text{IC}_{50}$  for XE-991 of  $0.96 \pm 0.4 \mu\text{M}$ ,  $n=7$  was determined (literature value 1-6  $\mu\text{M}$ ).




Fig.2: Block of KvLQT1/minK current with XE-991. Left: IT-plot showing the current amplitude in response to four increasing concentrations of XE-991. Right: Corresponding Hill fit.

Next, the effect on the blocker Bepridil was tested on the KvLQT1/minK currents. Figure 3 (left) shows the current–time plot of the peak amplitude in response to four increasing concentrations of Bepridil (0.05, 0.5, 5, 50  $\mu\text{M}$ ). Figure 3 (right) shows the corresponding Hill fit. The resulting  $\text{IC}_{50} = 8.96 \pm 1.0 \mu\text{M}$ ,  $n=8$  (literature value 5.3-10.5  $\mu\text{M}$ ).




Fig.3: Block of KvLQT1/minK current with Bepridil. Left: IT-plot showing the current amplitude in response to four increasing concentrations of Bepridil. Right: Corresponding Hill fit.

Furthermore, experiments were performed in order to evaluate Chromanol 293B on KvLQT1/minK currents. Figure 5 (left) shows the current–time plot of the peak amplitude in relation to four concentrations of Chromanol 293B (0.05, 0.5, 5, 50  $\mu\text{M}$ ). Figure 4 (right) shows the corresponding Hill fit. The resulting  $\text{IC}_{50}$  for Chromanol 293B =  $10.6 \pm 1.1 \mu\text{M}$ ,  $n=13$  (literature value 10-12.4  $\mu\text{M}$ ).




Fig.4: Block of KvLQT1/minK current with Chromanol 293B. Left: IT-plot showing the current amplitude in response to four increasing concentrations of Chromanol 293B. Right: Corresponding Hill fit.

### 3.3 Patch-clamp Success Rates

During validation cells showed stable expression levels up to passage 28 (higher passages were not tested). The following success rates were achieved using Q-Patch:

	Single hole	Multi hole
No of Q-Plates tested	5	6
Cell attachment (%)	99	100
100 MΩ < R <sub>mem</sub> < 1 GΩ (%)	28	-
R <sub>mem</sub> > 1 GΩ (%)	58	-
Whole cells (%)	96	100
Completed experiments (%)	73	100
Whole cell life time (min)	20	35

## 4 KvLQT1/MINK SEQUENCE

### 4.1 Human KvLQT1 Accession Number AF000571

Cloned cDNA sequence of KvLQT1 subunit was error-free and identical with AF000571 sequence:

```

ATG GCCGCGGCCTCCTCCCGCCAGGGCCGAGAGGAAGCGCTGGGGTTGGGGCCGCTGCCAGGCGCCGGCGGGGCAG
CGCGGGCCTGGCCAAGAAGTGCCCTTCTCGCTGGAGCTGGCGGAGGGCGCCGGCGGGCGGCGCGCTCTACGCGCCA
TCGCGCCCGGCGCCAGGTCGCGCCCTCGCTCCCGCCGCGCCGCGCCGCGCCCAAGTTGCCTCCGACCTTGGCC
CGCGCCCGCGGTGAGCCTAGACCGCGCGTCTCCATCTACAGCACGCGCCGCGCGGTGTTGGCGCGCACCCACGTCCAGG
GCCGCGTCTACAACCTCCTCGAGCGTCCACCGGCTGGAATGCTTCGTTTACCACCTCGCCGCTTCTCCTCATCGTCTGGTCT
GCCTCATCTTCAGCGTGTGCCACCATGAGCAGTATGCCGCCCTGGCCACGGGGACTCTCTTCTGGATGGAGATCGTGTCT
GGTGGTGTCTTCGCGGACGGAGTACGTGGTCCGCTCTGGTCCGCGGCTGCCGACGCAAGTACGTGGGCTCTGGGGGGC
GCTGCGCTTGGCCGGAAGCCATTTCCATCATCGACCTCATCGTGGTGTGGGCTCCATGGTGGTCTCTGCGTGGGCTCCA
AGGGGACAGGTGTTGCCACGTGCGCCATCAGGGGCATCCGCTTCTCGAGATCCTGAGGATGCTACACGTGACCGCCAGG
GAGGCACCTGGAGGCTCCTGGGCTCCGTGGTCTTCATCCACCGCCAGGAGCTGATAACCACCTGTACATCGGCTTCTGGG
CCTCATCTTCTCCTCGTACTTTGTGTACCTGGCTGAGAAGGACGCGGTGAACGAGTCAAGCCGCGTGGAGTTCCGCGACTAC
GCAGATGCGCTGTGGTGGGGGGTGGTACAGTCAACCATCGGCTATGGGGACAAGGTGCCCCAGACGTGGGTGGGAA
GACCATGCGCTCCTGCTTCTGTCTTTGCCATCTCCTTCTTGGCTCCAGCGGGGATTCTTGGCTCGGGGTTTGCCTGAA
GGTGCAGCAGAAGCAGAGGCAGAAGCACTTCAACCGGCAGATCCCGCGGCAGCCTCACTCATTAGACCGCATGGAGGT
GCTATGCTGCGGAGAACCCCGACTCCTCCACCTGGAAGATCTACATCCGGAAGGCCCCCGGAGCCACACTCTGCTGTAC
CCAGCCCAAACCAAGAAGTCTGTGGTGGTAAAGAAAAAAGTTCAAGCTGGACAAAGACAATGGGGTGACTCCTGGA
GAGAAGATGCTCACAGTCCCCATATCAGTGGACCCCGAGAAGAGCGGGGCTGGACCACTTCTGTCGACGGGTAT
GACAGTCTGTAAGGAAGAGCCCAACTGCTGGAAGTGAAGATGCCCCATTTATGAGAACCAACAGCTTCGCGGAGGAC
CTGGACTGGAAGGGGAGACTCTGCTGACACCCATCACCACATCTCACAGTGGGGAACACCATCGGGCCACCATTAAAG
GTCATTGACGCATGCAGTACTTTGTGGCCAAGAAGAAATTCAGCAAGCGCGGAAGCCTTACGATGTGCGGGACGTCATT
GAGCAGTACTCGAGGGCCACCTCAACCTCATGGTGCGCATCAAGGAGCTGCAGAGGAGGCTGGACCACTCATTGGGAA
GCCCTCACTGTTCTCCTGCTCAGAAAAGAGCAAGGATCGCGGCAGCAACACGATCGGGCGCCGCTGAACCGAGTAG
AAGACAAGGTGACGCAGCTGGACCAGAGGCTGGCACTCATCCGACATGCTTACCAGCTGCTCCTTGCACGGTGGCA
GCACCCCGGCAGCGGGCGGCCCCCGAGAGGGCGGGGCCACATCACCAGCCCTGGCGAGTGGCGGCTCCGTCGA
CCCTGAGCTTCTCCTGCCAGCAACACCCTGCCACCTACGAGCAGCTGACCGTGGCCAGGAGGGGCCCGATGAGGGGTC
CTGA

```

### 4.2 Human minK Subunit Accession Number AF135188

Cloned cDNA sequence of minK subunit was error-free and identical with AF135188 sequence:

```

ATGATCCTGTCTAACCCACAGCGGTGACGCCCTTCTGACCAAGCTGTGGCAGGAGACAGTTCAGCAGGGTGGCAACATG
TCGGGCTGGCCGCAAGTCCCCCGCAGCAGTGACGGCAAGCTGGAGGCCCTCTACGTCTCATGGTACTGGGATTCCTCG
GCTTCTTACCCTGGGCATCATGCTGAGCTACATCCGCTCCAAGAAGCTGGAGCACTCGAACGACCCATTCAACGTCTACAT
CGAGTCCGATGCCTGGCAAGAGAAGGACAAGGCCTATGTCCAGGCCGGGCTCTGGAGAGCTACAGGCTGTGCTATGCTGT
TGAAAACCATCTGGCCATAGAACAACCAACACACCTTCTGAGACGAAGCCTTCCCCATGA

```



## 5 CONTACT INFORMATION

### 5.1 Contact Address for Technical Support & Ordering Information

- B'SYS GmbH  
Technology Center Witterswil  
Benkenstrasse 254  
4108 Witterswil  
Switzerland

Tel: +41 61 721 77 44

Fax: +41 61 721 77 41

Email: [info@bsys.ch](mailto:info@bsys.ch)

Web: [www.bsys.ch](http://www.bsys.ch)